Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–mutated,
stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or …

Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …

Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …

Multiorgan and Renal Tropism of SARS-CoV-2 In this autopsy series, the authors found that
SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart…

Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…